Sanofi: Oddo BHF raises its target price on the stock
(CercleFinance.com) - Oddo BHF maintains its 'outperform' rating on Sanofi shares, with its target price raised from E105 to E119.
The analyst reports that positive topline results from the Hercules trial (secondary progressive non-active multiple sclerosis) have reassured the market about tolebrutinib's ambitions.
The publication of tolebrutinib's full results at ECTRIMS on September 20 could lead to volatility in the share price.
The broker points out that 2025 will also be marked by the
results of lunsekimig in asthma, its Oral TNFR1si in psoriasis and above all itepekimab (anti-IL33) in COPD (chronic bronchitis in ex-smokers, corresponding to 70% of the market).
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
The analyst reports that positive topline results from the Hercules trial (secondary progressive non-active multiple sclerosis) have reassured the market about tolebrutinib's ambitions.
The publication of tolebrutinib's full results at ECTRIMS on September 20 could lead to volatility in the share price.
The broker points out that 2025 will also be marked by the
results of lunsekimig in asthma, its Oral TNFR1si in psoriasis and above all itepekimab (anti-IL33) in COPD (chronic bronchitis in ex-smokers, corresponding to 70% of the market).
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.